Last reviewed 2026-05-20 · How we verify

Tromaril (ENFENAMIC ACID)

Phase 2 active Small molecule ✓ Verified May 2026

Tromaril (generic name: ENFENAMIC ACID) is a enfenamic acid drug. It is currently in Phase 2 development.

Tromaril works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.

Tromaril is a small molecule. It is also known by the synonyms ACIDE ENFENAMIQUE, ACIDO ENFENAMICO, and ENFENAMIC ACID.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ENFENAMIC ACID
Drug class	enfenamic acid
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Think of prostaglandins like messengers that tell your body to feel pain and become inflamed. Tromaril blocks these messengers, which can help reduce pain and swelling. This can be especially helpful for people with conditions like arthritis or menstrual cramps.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tromaril CI brief — competitive landscape report
Tromaril updates RSS · CI watch RSS

Frequently asked questions about Tromaril

What is Tromaril?

Tromaril (ENFENAMIC ACID) is a enfenamic acid drug.

How does Tromaril work?

Tromaril works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.

What is the generic name of Tromaril?

ENFENAMIC ACID is the generic (nonproprietary) name of Tromaril.

What drug class is Tromaril in?

Tromaril belongs to the enfenamic acid class. See all enfenamic acid drugs at /class/enfenamic-acid.

What development phase is Tromaril in?

Tromaril is in Phase 2.

Drug class: All enfenamic acid drugs
Therapeutic area: All drugs in Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing